A Phase 3 interventional study of Surovatamig and Rituximab in Large B-cell Lymphoma, sponsored by AstraZeneca. Not yet recruiting. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
This is a study to evaluate the efficacy of surovatamig combined with rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) in participants aged 18 to \< 80 years of age with previously untreated large B-cell lymphoma (LBCL) with International Prognostic Index (IPI) score 2 to 5.
This is an open-label, multicentre, randomised controlled study.
The study will have the following sequential periods:
The study has 2 arms:
885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.
This study's planned enrollment of 1,200 is above the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.
Browse Lymphoma, B-Cell studies →AstraZeneca is the lead sponsor of 3,499 studies on the registry; 270 are open to participants now.
Of its 368 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive surovatamig in combination with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy according to standard of care (SoC).
Drug: Surovatamig · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone
Participants will receive either R-CHOP or Pola-R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone \[or equivalent\]) and polatuzumab vedotin) according to SoC.
Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Polatuzumab vedotin
Fully human bispecific monoclonal immunoglobulins (Ig) G4 antibody
Also known as: AZD0486
Rituximab will be administered to participants as per SoC.
Cyclophosphamide will be administered to participants as per SoC.
Doxorubicin will be administered to participants as per SoC.
Vincristine will be administered to participants as per SoC.
Prednisone (or equivalent) will be administered to participants as per SoC.
Polatuzumab vedotin will be administered to participants as per SoC.
Progression free survival (PFS) as assessed by Blinded Independent Central Review (BICR)
The PFS is defined as the time from randomisation to the first occurrence of disease progression as determined by an Independent Review Committee (IRC), or death from any cause, whichever occurs first.
Time frame: Up to 10 years
Overall survival (OS)
The OS is defined as the time from randomisation to death due to any cause.
Time frame: Up to 10 years
PFS as assessed by the investigator
The PFS is defined as the time from randomisation to the first occurrence of disease progression as determined by the investigator, or death from any cause.
Time frame: Up to 10 years
Event-free survival efficacy (EFSeff)
The EFSeff is defined as the time from randomisation to the first occurrence of disease progression, relapse, death from any cause, initiation of new antilymphoma treatment for an efficacy-related reason.
Time frame: Up to 10 years
Overall response (OR) rate
The OR is defined as the percentage of participants who achieve a partial response (PR) or complete response (CR), as assessed by the investigator and IRC separately.
Time frame: Up to 10 years
CR rate
The CR is defined as the percentage of participants who achieve a CR, as assessed by the investigator and IRC separately.
Time frame: Up to 10 years
Duration of response (DoR)
The DoR is defined as the time from the first documented OR to disease progression or death from any cause, whichever occurs first, as assessed by IRC.
Time frame: Up to 10 years
Duration of Complete Response (DOCR)
The DOCR is defined as the time from the first occurrence of a documented CR to disease progression, or death, whichever occurs first, as assessed by IRC.
Time frame: Up to 10 years
Disease-free survival (DFS)
The DFS is defined as the time from a documented CR at the end of treatment to disease progression or death from any cause, whichever occurs first, as assessed by the investigator and IRC separately.
Time frame: Up to 10 years
No study locations are listed for this record.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Surovatamig